Inventor Takes Fight Against Google and Microsoft Back to USPTO on Sotera Issue Following CAFC Rehearing Denial

One day after her petition for rehearing was denied by the U.S. Court of Appeals for the Federal Circuit (CAFC), pro se inventor Carrie Hafeman has filed a petition for Extraordinary Director Review and Sua Sponte Review with the U.S. Patent and Trademark Office (USPTO). The petition asks the Director to vacate institution and the Final Written Decisions in six related inter partes reviews (IPRs) due to alleged Sotera Stipulation violations by Google and Microsoft.  

Federal Circuit Upholds PTAB Findings That Google Failed to Prove VR Viewer Patent Claims Obvious

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today in Google LLC v. DDC Technology, LLC, affirming the Patent Trial and Appeal Board’s (PTAB) determinations that Google did not prove claims in three DDC Technology patents directed to hand-held virtual reality (VR) viewers unpatentable as obvious.

GAO Report: USPTO’s Backlog Reduction Goals Unsustainable if Workforce Strain, Examiner Attrition Continue

Today, the U.S. Government Accountability Office (GAO) published a report on efforts at the U.S. Patent and Trademark Office to reduce the current backlog of unexamined U.S. patent applications at the agency, which announced its intention to reduce the backlog to fewer than 599,000 patent applications last September. The GAO’s report casts a pall on those efforts, which have been contributing to patent examiner attrition that, left unchecked, could prevent the USPTO from reaching its backlog reduction goal within the next five years.

Second Circuit Follows Third Circuit in Applying Broad ‘Use’ Definition for DTSA Misappropriation Claims

Yesterday, the U.S. Court of Appeals for the Second Circuit reversed and remanded the Southern District of New York’s dismissal of trade secret misappropriation claims filed against fintech company Arcesium by rival SS&C Technologies. Deciding that a broad definition of “use” under the Defend Trade Secrets Act (DTSA) was consistent with Second Circuit case law, the appellate court held that the district court erred in finding no misappropriation of SS&C’s alleged trade secrets and improperly credited Arcesium’s explanation of emails attached to SS&C’s complaint at the motion to dismiss stage.

CJEU Advocate General Outlines Copyright Limits for AI News Summaries

Advocate General Maciej Szpunar of the Court of Justice of the European Union (CJEU) issued an opinion on Tuesday in the first case on generative AI to reach the Court. The opinion ultimately held that “the retrieval and reuse, in real time, of online press publications by AI chatbots in order to generate answers to user queries may, in certain circumstances, infringe the rights of press publishers.” The opinion is nonbinding on the CJEU.

Rare Disease Treatment Patents after Amgen: Can Claims Cover Untested Genetic Mutations?

On October 14, 2026, the Food and Drug Administration (FDA) announced the Rare Disease Framework Initiative. The goal of this effort is quite essential for patients with rare (orphan) diseases – to develop an approach for assessing medicines for orphan diseases with a focus on the evidence that can be gathered for this assessment. The FDA proposes to include disease characteristics, patient needs, patient population size, and characteristics of orphan medications. The initiative does not itself establish new approval standards. Although the initiative relates to regulatory evidence matters, it also raises a separate legal question about the evidence needed to support patent claim scope.

When AI Adoption Outpaces IP Protection: The Risks Companies Must Address | IPWatchdog Unleashed

This week on IPWatchdog Unleashed, we have a discussion about the IP risks associated with AI use and adoption, with Stephanie Curcio, Marlene Valderrama, Kendra Ervin and Rinat Shangeeta. The discussion reveals a consequential gap with how businesses are deploying AI. Many companies are moving faster to adopt AI than their governance, contracting and IP review processes can accommodate. For those responsible for protecting innovation and confidential information, the challenge is ensuring that enthusiasm for AI adoption does not obscure the consequences of how these tools are actually used.

Subscribe to IPWatchdog

This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.

Get Email Updates